NCT00982371

Brief Summary

The number of people with type 2 diabetes is growing. This puts a lot of pressure on the health care systems. Type 2 diabetes is often associated with health problems, like poor eyesight, muscle coordination, muscle strength, and blood flow. Poor bone health may also be a concern for people with type 2 diabetes. A large proportion of people with type 2 diabetes will break a bone in their lifetime. The risk of this happening in older people with type 2 diabetes is greater than the risk in older people without diabetes. Fracturing a bone can be very painful, and lead to serious consequences, especially if the individual experiences a hip fracture. The elevated fracture risk, seen in those with type 2 diabetes, is puzzling because people with type 2 diabetes often appear to have normal, healthy bones compared to people of the same age without diabetes. Bone micro-structure, which is not assessed by traditional bone densitometry systems (ie: DXA) contributes to overall bone strength. The hypothesis of this study is that bone micro-structure is of poorer quality (reduced trabecular thickness, increased trabecular spacing) in postmenopausal women with type 2 diabetes, compared to age-matched control participants.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2008

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2008

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

September 21, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 23, 2009

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

June 19, 2012

Status Verified

June 1, 2012

Enrollment Period

3.2 years

First QC Date

September 21, 2009

Last Update Submit

June 17, 2012

Conditions

Keywords

type 2 diabetes mellitusosteoporosisbone qualitymagnetic resonance imagingfracturepostmenopausal women >65 years old

Outcome Measures

Primary Outcomes (1)

  • 1 Tesla peripheral MRI assessment at non dominant distal radius: Trabecular bone micro-architecture parameters Tb.Th, Tb.Sp, Tb.N, BV/TV, bone CSA, marrow space

    MRI scan complete approximately 1 month after participant is enrolled

Secondary Outcomes (1)

  • Calcium, vitamin D and vitamin K dietary intakes; TUG (sec); grip strength; DXA assessment of hip, lumbar spine, total body; physical activity

    baseline

Study Arms (2)

Controls

female; \>65 years old; BMI \>25kg/m2; postmenopausal \>5 yrs; NO clinical diagnosis of type 2 diabetes for \>5 years (according to Canadian Diabetes Association criteria)

Type 2 Diabetes

female; \>65 years old; BMI \>25kg/m2; postmenopausal \>5 yrs; clinical diagnosis of type 2 diabetes for \>5 years (according to Canadian Diabetes Association criteria)

Eligibility Criteria

Age65 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsOlder Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

female; \>65 years old; BMI \>25kg/m2; postmenopausal \>5 yrs

You may qualify if:

  • female
  • \>= 65 years old
  • postmenopausal for \> 5 years (WHO definition of menopause)

You may not qualify if:

  • currently taking osteoporosis related medication (HRT, SERM, bisphosphonate, PTH, calcitonin, fluoride)
  • had cancer in past 10 years, likely to metastasize to bone (ie: breast, lung)
  • have intrinsic bone disease (ie: Paget's Disease, Cushings syndrome)
  • have untreated malabsorption syndrome (ie: Celiac Disease)
  • renal insufficiency (CrCl \<30ml/min)
  • hyperparathyroidism, hypoparathyroidism
  • chronic systemic glucocorticosteroid use \> 3mos, dose\>2.5mg daily

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

McMaster University

Hamilton, Ontario, L8N 3Z5, Canada

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2OsteoporosisFractures, Bone

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesBone Diseases, MetabolicBone DiseasesMusculoskeletal DiseasesWounds and Injuries

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 21, 2009

First Posted

September 23, 2009

Study Start

September 1, 2008

Primary Completion

December 1, 2011

Study Completion

December 1, 2011

Last Updated

June 19, 2012

Record last verified: 2012-06

Locations